INDP

  INDP is TODAY’S #1 ALERT

Hey team, there’s an urgent trade idea I’d like to get on your radar right away.

This is a stock I alerted twice in 2024…

In May, it went on to climb 34% the day I alerted it. In October, it beat that performance with a 41% rally.

I was glad to catch both of those moves, but once you take a look at its chart, you’ll see there are many similar moves that I missed…

Today’s “tactical trade” alert is Indaptus Therapeutics, Inc. (INDP).

This is a clinical-stage biotech that has been steadily advancing its lead candidate.

But just on Tuesday, the company made an announcement that could possibly change everything.

As you’ll read below, the company has been working toward this moment for some time, and its lead candidate may get its chance to truly shine this year.

The announcement led one analyst to reiterate his BUY rating (with a 530% upside price target), but I think it has flown under the radar of casual investors.

Today could be a very big day for INDP as the news sinks in. Tune in to see if we see another double-digit move!

INDP is a fascinating little company that’s worth looking into…

It’s a clinical-stage, NYC-based biotech company dedicated to pioneering innovative cancer and viral infection treatments.

INDP began a Phase 1 clinical trial for its lead candidate, Decoy20, in December 2022, and the first patient dosing was in March 2023.

The company had been sitting on dozens of issued or granted patents based on tech developed by Indaptus Founder and Chief Scientific Officer, Dr. Michael Newman, but it’s now fully off to the races.

I looked into Decoy20 and found it unusually interesting…

It was inspired by the observation that tumors sometimes regress in the presence of a bacterial infection. The theory is that the infection may activate the immune system in a way the cancer doesn’t.

But you obviously don’t want to infect cancer patients with bacteria that could cause them sustained sickness.

That’s where Decoy20 comes in.

It contains “proprietary, attenuated and killed non-pathogenic gram-negative bacteria that have demonstrated broad anti-tumor and anti-viral activity.”

In layman’s speak, Decoy20 is weakened bacteria that INDP believes will act as a “decoy” to activate broad anti-tumor responses from both the innate and adaptive immune systems.

The bacteria will then pass quickly from the system without making the patient too sick.

Here’s a really great video about how it all works.

To date — and it’s still in the early stages — the Phase 1 trial has borne out the company’s theories.

In November 2023, the company released interim data from the first group of patients to receive Decoy20. According to the press release:

The interim data . . . demonstrated that as of August 31, 2023, each of the first cohort participants experienced transient activation of biomarkers associated with innate and/or adaptive immune responses, and generally expected transient adverse events, both associated with predicted rapid clearance of Decoy20.

That last part is important because the idea is for Decoy20 to be in and out — to cause a sustained immune response but not a sustained bacterial infection.

This lent weight to what had until then been just theory. The company presented the data to the Society for Immunotherapy of Cancer. You can read more about that here.

Last April, INDP presented positive “mechanism of action” data at the annual meeting of the prestigious American Association for Cancer Research.

Dr. Newman said that the new data were “consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.”

INDP began the multi-dose portion of the Decoy20 trial the next month, and revealed encouraging safety data in November at the Society for Immunotherapy of Cancer 2024 Annual Meeting.

That same month, Dr. Newman published a study about the Decoy approach in Frontiers in Immunology, a peer-reviewed journal.

So far, data have shown that Decoy20 disappears from the blood within 30–120 minutes and that it produces “transient induction in plasma of over 50 cytokines and chemokines, many of which have been associated with stimulation of innate and/or adaptive immune responses.”

In September, INDP CEO Jeffrey Meckler gave an interesting presentation which included a slide deck explaining where the Decoy20 trial stands…

He explained that the company is most looking forward to the combination therapy portion of the trial since Decoy20 had tremendous results — including tumor eradication rates of 80-100% — in mice studies when combined with an NSAID and an anti-PD-1 checkpoint inhibitor.

He also pointed out that if Decoy20 works the way the company thinks it will, it could be a game changer not just for a whole host of cancer treatments, but for viral infections including Hepatitis B as well.

Just on Tuesday, the company announced it has “advanced to a new expansion arm of its Phase 1b/2 clinical trial of Decoy20” which will “evaluate the combination of Decoy20 with BeiGene’s PD-1 checkpoint inhibitor, tislelizumab, with a focus on safety, dose optimization, and early signs of anti-tumor activity.”

Mr. Meckler said this is a “pivotal step” for the company that is “laying the groundwork for what could be a game-changing approach to treating solid tumors.”

Analysts are very bullish on INDP, with the Maxim Group reiterating a BUY rating with a $5.00 12-month price target just last week. H.C. Wainwright reiterating its BUY rating with a $12.00 price target in October.

Those targets represent potential upsides of 530% and 1,400%, respectively.

Those are some things that jumped out at me when I did my research, but be sure to do your own research as well. And always approach your trading in a responsible manner, remembering that trading is very risky. Nothing is ever guaranteed, so never trade with more than you can afford to lose. 

Please read the full disclaimer at the bottom of this email as well so you are aware of additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

Bottom line: You’ll want INDP at the top of your watchlist as the trading day unfolds. We got to see great rallies the last two times I brought up INDP… let’s see what we get today!

To Your Success,

Jeff Bishop

*Just so you know, what you’re reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let’s be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren’t what you’d call “typical.”

Just a quick heads up about this ad you’re reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received fifteen thousand dollars (cash) from Legends Media for advertising Indaptus Therapeutics, Inc for a one-day marketing program on March 20, 2025. Before this, we received fifteen thousand dollars (cash) from Legends Media for advertising Indaptus Therapeutics, Inc for a one-day marketing program on October 22, 2024 and also fifteen thousand dollars (cash) from Legends Media for advertising Indaptus Therapeutics, Inc for a one-day marketing program on may 29, 2024, and also fifteen thousand dollars from Sica Media for advertising Indaptus Therapeutics, Inc. from a period beginning on November 6 through November 7, 2023.   These amounts were paid by someone else not connected to Indaptus Therapeutics, Inc. It might be obvious, but whoever paid for this might own shares and is likely looking to sell some or all of them at any time after we send out this information, which might affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither RagingBull nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as our program ends, though that is not always the case.

Now, diving right into Indaptus Therapeutics, Inc might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there’s exceptional risk involved in trading. This isn’t small potatoes we’re talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We’re shining a light on the good stuff about the company here, but it’s on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we’re not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can’t wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who’s licensed to give you real advice. To be clear, 

Neither Raging Bull nor its owners, employees, or independent contractors are registered as a secur1ties br0ker-dealer, br0ker, 1nvestment advis0r (IA), or IA rep’s with the SEC, any state securities regulat0ry authority, or any self-regulat0ry organization.

So, that’s the scoop! If you’re intrigued and want to learn more about the companies we talk about, hit up the SEC’s website to dig into their filings and see the full picture.